AstraZeneca agreed to acquire ex‑China rights to Jacobio Pharma’s clinical‑stage pan‑KRAS inhibitor JAB‑23E73, paying $100 million upfront and underwriting further development globally. The UK drugmaker plans to advance the oral inhibitor in indications driven by KRAS mutations, expanding its oncology portfolio. AstraZeneca framed the transaction as a strategic bet on a multi‑target KRAS compound emerging from China’s clinical ecosystem. The deal also reflects Big Pharma’s continued sourcing of KRAS chemistry and clinical programs from Chinese biotech partners.